Medical/Pharmaceuticals
QBIOTICS WELCOMES STEPHEN DOYLE AS CHIEF EXECUTIVE OFFICER
* Stephen Doyle has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and Boehringer Ingelheim. He was most recently Chief Business Officer at Aslan Pharmaceuticals. * Mr Doyle brings extensive knowledg...
2024-08-05 19:00
1795
So-Young to Report Second Quarter 2024 Financial Results on August 23, 2024
BEIJING, Aug. 5, 2024 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced that it will report its financ...
2024-08-05 17:00
2455
Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Ocular Surgery Relief and Recovery
TAIPEI, Aug. 5, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals (" Formosa", 6838.TWO) announced today that the company has entered into an exclusive licensing agreement with Apotex Inc. ("Apotex"), for exclusive rights inCanada to the commercialization of clobetasol propionate ophthalmi...
2024-08-05 16:30
1558
INAUGURAL NUHS SCIENTIFIC & INNOVATION SUMMIT CHAMPIONS PREDICTIVE, PRECISE AND PERSONALISED CARE
From digital twin technology to leveraging AI in tackling obesity, the NUHS Scientific & Innovation Summit is a congregation of the brightest minds in cutting-edge medicine – with patients' utmost care at heart SINGAPORE, Aug. 3, 2024 /PRNewswire/ -- Hepatocellular carcinoma (HCC) is one of the ...
2024-08-03 14:02
3552
Novel Non-Covalent Hits Against GPX4 Identified Using the RiDYMO® Reinforced Dynamics Platform of DP Technology
Research on ferroptosis is gaining momentum, but the development of small molecule inhibitors faces numerous challenges BEIJING, Aug. 1, 2024 /PRNewswire/ -- Glutathione peroxidase 4 (GPX4) is recognized as a critical regulator of ferroptosis, playing a significant role in lipid and amino acid m...
2024-08-01 17:00
1744
WuXi Biologics' Four Manufacturing Facilities and Biosafety Testing Center Certified Again by European Medicines Agency for Ten Biologics
WUXI and SUZHOU, China, Aug. 1, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that four manufacturing facilities and Suzhou Biosafety Testing Center inChina have received Good Ma...
2024-08-01 15:00
2669
Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs
BOSTON, July 31, 2024 /PRNewswire/ -- Recently, Shanghai Medicilon Inc. ("Medicilon") and Jiangsu Hengrui Pharmaceuticals Co., Ltd. ("Hengrui Pharma") reached a strategic collaboration agreement.The cooperative efforts will focus on preclinical evaluation of new drug modalities, particularly ADCs...
2024-07-31 22:39
1353
SURGLASSES Announces Successful First Clinical Implementation of Caduceus S AR Surgical Navigation System in Thailand
ONTARIO, Calif., July 31, 2024 /PRNewswire/ -- Leading augmented reality (AR) medical technology company SURGLASSES today announced that, in collaboration with exclusive distributor Goodlifeintertrade.co. Ltd., it has successfully registered and clinically implemented its AR-based Caduceus S surg...
2024-07-31 21:00
2015
JelloX Biotech collaborates with Mayo Clinic to develop AI enhanced 3D pathology imaging technology
HSINCHU, July 31, 2024 /PRNewswire/ -- JelloX Biotech Inc. ('JelloX') is pleased to announce that it has entered into a collaboration through a know-how agreement with Mayo Clinic to further develop and validate their 3D digital imaging and AI analysis technology. JelloX previously participated i...
2024-07-31 17:00
1294
Fapon Delivers Customized IVD Solutions for the US Market at ADLM 2024
CHICAGO, July 31, 2024 /PRNewswire/ -- Fapon, a global leading life sciences company, is showcasing its innovative IVD total solutions at ADLM 2024 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo), fromJuly 28 to August 1 in Chicago. Committed to supporting local partners, we del...
2024-07-31 14:42
1147
FDA Grants Orphan Drug Designation (ODD) Status to Zymedi's ZMA001 for Pulmonary Arterial Hypertension
INCHEON, South Korea, July 30, 2024 /PRNewswire/ -- Zymedi (CEO Sunghoon Kim) announced that its first-in-class antibody treatment ZMA001, currently in development for pulmonary arterial hypertension (PAH), has been designated as an Orphan Drug by the U.S. Food and Drug Administration (FDA). Pul...
2024-07-31 08:00
1551
Porton Advanced and Geneseed Biotech Enter into Strategic Collaboration to Focus on Advancing circRNA Innovative Therapeutics
SUZHOU, China, July 30, 2024 /PRNewswire/ -- On July 29, 2024, Porton Advanced Solutions ("Porton Advanced") announced that it had reached a strategic cooperation with Guangzhou Geneseed Biotech Co., Ltd ("Geneseed Biotech"). Both sides will combine their respective strengths in the field of gene...
2024-07-30 22:00
2308
Baird Medical Announces Engagement and Education Program for the Development of Thyroid Microwave Ablation Technology
FRISCO, Texas, July 30, 2024 /PRNewswire/ -- Baird Medical Devices, Inc. ("Baird Medical"), a leading developer and provider of microwave ablation ("MWA") medical devices inChina and the United States, today announced a cross-market engagement and education program designed at fostering both kno...
2024-07-30 17:00
1589
Synthetica Pioneering Closes a Series A Funding Round to Support Development of Oncolytic Bacterial Therapy for Solid Tumors
SHENZHEN, China, July 30, 2024 /PRNewswire/ -- Shenzhen Synthetica Pioneering Co., Ltd. (Synthetica), a biotech startup specializing in synthetic biology for engineering novel living bacterial therapeutics, has recently closed a Series A funding round, led by Boehringer Ingelheim Venture Fund and...
2024-07-30 14:00
1489
Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis
SEONGNAM, South Korea, July 29, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based inSouth Korea developing novel drugs for fibrosis and cancer, today announced that patient participant enrollment has been completed in the Phase 2 clinical study of BBT-...
2024-07-30 06:00
1449
Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-in-Class PRS Inhibitor, Bersiporocin
SEOUL, South Korea, July 29, 2024 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOsChang-Jae Lee and Seongsoo Park) announced a significant milestone in the development of 'Bersiporocin (DWN12088)', a first-in-class PRS inhibitor for idiopathic pulmonary fibrosis (IPF), has taken a significant ste...
2024-07-29 20:00
1689
Despite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up 16.0% QoQ and Adjusted Non-IFRS Net Profit Up 28.5% QoQ
* Revenue Reached RMB9,259 Million in the Second Quarter, Excluding COVID-19 Commercial Projects, Up 0.3% Year-over-Year * Revenue Reached RMB17,241 Million for the First Half, Excluding COVID-19 Commercial Projects, Down 0.7% Year-over-Year * Net Profit Attributable to the Owners of the Com...
2024-07-29 19:05
4187
Akeso's sBLA for Ivonescimab in 1L Treatment of PD-L1 Positive NSCLC Accepted by NMPA
HONG KONG, July 29, 2024 /PRNewswire/ -- Akeso (9926.HK) is delighted to announce that the supplemental biologics license application (sBLA) for its independently developed, world's first-in-class PD-1/VEGF bispecific antibody drug, 依达方® (generic name: ivonescimab Injection), as a monotherapy for...
2024-07-29 17:26
1658
111 to Announce Second Quarter 2024 Unaudited Financial Results on August 29, 2024 - Conference Call to Follow
SHANGHAI, July 29, 2024 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced that it will repor...
2024-07-29 13:00
1479
Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder
PRINCETON, N.J., July 28, 2024 /PRNewswire/ -- Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sales of innovative medications, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's ERZOFRI® (pa...
2024-07-28 21:48
2856
Week's Top Stories
Most Reposted
Agoda Partners with Sands China to Boost Tourism
[Picked up by 316 media titles]
2024-09-05 11:00The Beach Grill Unveils Exciting New Dishes: Elevating The Beachfront Dining Experience
[Picked up by 297 media titles]
2024-09-05 11:21
povo2.0, Japan's favourite digital telco, achieves highest user engagement and customer satisfaction rates with Circles' SaaS technology
[Picked up by 294 media titles]
2024-09-06 10:00Armacell will take complete ownership of the successful aerogel joint venture, AJA, following an agreement with JIOS Aerogel
[Picked up by 285 media titles]
2024-09-02 14:00Shiperoo Pioneers Tech-led Retail Returns and Fulfilment with AUD 30 Million Investment in Robotic Automated Facilities in Australia and New Zealand
[Picked up by 276 media titles]
2024-09-04 09:12
Most Read
Shiperoo Pioneers Tech-led Retail Returns and Fulfilment with AUD 30 Million Investment in Robotic Automated Facilities in Australia and New Zealand
2024-09-04 09:12
8836
Agoda Partners with Sands China to Boost Tourism
2024-09-05 11:00
8397
The Beach Grill Unveils Exciting New Dishes: Elevating The Beachfront Dining Experience
2024-09-05 11:21
6557